4.4 Article

Clinical application effect of Pembrolizumab in the treatment of advanced cutaneous malignant melanoma

期刊

AMERICAN JOURNAL OF TRANSLATIONAL RESEARCH
卷 13, 期 5, 页码 5380-5385

出版社

E-CENTURY PUBLISHING CORP

关键词

Advanced cutaneous malignant melanoma; Pembrolizumab; chemotherapy; clinical efficacy; adverse reaction

资金

  1. Natural Science Foundation of Hainan Province [817338]
  2. Hainan Province in 2019-2021 Provincial Key Subject Construction Project of Traditional Chinese Medicine (The Oncology Department) [S100111.401]

向作者/读者索取更多资源

The study found that PEM can improve the short-term clinical effective recovery rate, long-term survival time, and prognosis survival rate of patients with cutaneous malignant melanoma, with no increased incidence of drug-related adverse reactions.
Objective: To investigate the clinical application value of Pembrolizumab (PEM) in the treatment of advanced cutaneous malignant melanoma (ACMM). Methods: The data of 56 patients with ACMM were retrospectively analyzed. According to the treatment methods, they were divided into a control group (30 cases) and an observation group (26 cases). Patients in the control group were given chemotherapy with Temozolomide (TEM), and patients in the observation group were treated with PEM on the basis of the treatment provided to the control group. The short-term therapeutic efficacy, long-term survival rate and the incidence of adverse reactions were compared between the two groups. Results: After treatment, the short-term clinical effective rate was higher in the observation group than that in the control group (P<0.05). In addition, the survival time in the observation group was longer than that in the control group (P<0.001); and the one-year survival rate was higher in the observation group (53.85% vs. 40.00%, P>0.05). No statistical difference was found in the incidence of adverse reactions between the two groups (P>0.05). Conclusion: PEM can improve the short-term clinical effective recovery rate, long-term survival time and prognosis survival rate of patients with cutaneous malignant melanoma, with no increased incidence of drug-related adverse reactions. It is relatively safe and worthy of front-line clinical promotion and application.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.4
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据